Latest Conference Articles

November 19th 2016, 10:35pm

Society for Neuro-Oncology Annual Meeting

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

November 19th 2016, 9:40pm

Society for Neuro-Oncology Annual Meeting

November 19th 2016, 6:47am

Society for Neuro-Oncology Annual Meeting

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

November 19th 2016, 6:19am

Society for Neuro-Oncology Annual Meeting

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

November 19th 2016, 3:05am

Society for Neuro-Oncology Annual Meeting

November 19th 2016, 2:54am

Society for Neuro-Oncology Annual Meeting

November 19th 2016, 2:30am

Society for Neuro-Oncology Annual Meeting

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

November 18th 2016, 5:15am

Society for Neuro-Oncology Annual Meeting

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

November 18th 2016, 4:54am

Society for Neuro-Oncology Annual Meeting

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

November 18th 2016, 4:26am

Society for Neuro-Oncology Annual Meeting

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

November 18th 2016, 3:47am

Society for Neuro-Oncology Annual Meeting

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

November 18th 2016, 3:23am

Society for Neuro-Oncology Annual Meeting

The gene for an anticancer drug was successfully transduced in high-grade gliomas, which resulted in an improvement in overall survival, according to data from a phase I trial of Toca 511.

November 17th 2016, 9:58pm

AASLD Liver Meeting

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

November 17th 2016, 9:28pm

AASLD Liver Meeting

​Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.

November 17th 2016, 9:18pm

AASLD Liver Meeting

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

November 17th 2016, 1:19am

SMR Congress

Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.

November 15th 2016, 5:11am

AASLD Liver Meeting

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

November 15th 2016, 4:30am

PER® New York Lung Cancer Symposium

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

November 15th 2016, 4:21am

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

November 15th 2016, 3:13am

PER® New York Lung Cancer Symposium

Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.